The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
Arch. bronconeumol. (Ed. impr.)
; 59(9)sep. 2023. graf, tab
Artículo
en Inglés
| IBECS
| ID: ibc-224998
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
The respiratory syncytial virus (RSV) causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon. RSV immunization should be in place from season 2023/2024 onwards. Doing so requires thoughtful but swift steps. This paper reflects the view of four immunization experts on the efforts being made across the globe to accommodate the new immunization options and provides recommendations organized around five priorities (I) documenting the burden of RSV in specific populations; (II) expanding RSV diagnostic capacity in clinical practice; (III) strengthening RSV surveillance; (IV) planning for the new preventive options; (V) achieving immunization targets. Overall, Spain has been a notable example of converting RSV prevention into a national desideratum and has pioneered the inclusion of RSV in some of the regional immunization calendars for infants facing their first RSV season. (AU)
Texto completo:
Disponible
Colección:
Bases de datos nacionales
/
España
Base de datos:
IBECS
Asunto principal:
Virus Sincitial Respiratorio Humano
/
Infecciones por Virus Sincitial Respiratorio
Límite:
Niño
/
Femenino
/
Humanos
/
Masculino
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Arch. bronconeumol. (Ed. impr.)
Año:
2023
Tipo del documento:
Artículo
Institución/País de afiliación:
Asociación Española de Vacunología/Spain
/
Hospital Clínico Universitario and Universidad de Santiago de Compostela/Spain
/
Hospital Universitari Vall dHebron/Spain
/
Nazaret Health Centre/Spain